4.3 Article

Association of GA/HbA1c ratio and cognitive impairment in subjects with type 2 diabetes mellitus

Journal

JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 30, Issue 8, Pages 1452-1455

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2016.08.008

Keywords

GA/HbA1c ratio; Cognitive impairment; Type 2 diabetes mellitus; Hypoglycemia; Hasegawa dementia scale-revised

Funding

  1. Novo Nordisk Pharma
  2. Sanwa Kagaku Kenlcyusho
  3. Takeda
  4. Taisho Pharmaceutical Co., Ltd
  5. Kowa
  6. MSD
  7. Sumitomo Dainippon Pharma
  8. Novartis
  9. Mitsubishi Tanabe Pharma
  10. AstraZeneca
  11. Nippon Boehringer Ingelheim Co., Ltd
  12. Chugai
  13. Daiichi Sanlcyo
  14. Sanofi
  15. Novo Nordisk
  16. Lilly
  17. Boehringer Ingelheim
  18. Ono Pharma
  19. Daiichi Sankyo
  20. Pfizer
  21. Kissei Pharma
  22. Astellas
  23. Taisho Pharma

Ask authors/readers for more resources

Aims: The aim of this study was to search for factors influencing cognitive impairment and to clarify the association between the fluctuation of blood glucose levels and cognitive impairment in elderly Japanese subjects with type 2 diabetes. Methods: We recruited 88 relatively elderly subjects (>= 65 years old) with type 2 diabetes who were hospitalized in Kawasaki Medical School from January 2014 to December 2015. We evaluated the fluctuation of blood glucose levels with glycoalbumin (GA)/hemoglobin Alc (HbAlc) ratio, and estimated cognitive impairment with Hasegawa dementia scale-revised (HDS-R) score and mini mental state examination (MMSE) score. Results: Multivariate analyses showed that GA/HbAlc ratio and urinary albumin excretion, but not hypoglycemia, were independent determinant factors for cognitive impairment in elderly Japanese subjects with type 2 diabetes. Conclusions: The fluctuation of blood glucose levels per se is closely associated with cognitive impairment in elderly subjects with type 2 diabetes even when hypoglycemia is not accompanied. Since it is very easy to calculate GA/HbAlc ratio, we should check this ratio so that we can reduce the fluctuation of blood glucose levels especially in elderly subjects with type 2 diabetes. (C) 2016 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available